Chiba, Japan

Fumitada Yamamoto

This inventor holds 1 USPTO granted patent. Top assignees: Idemitsu Kosan Company, Limited, Nippon Chemiphar Co., Ltd.. Active years: 1977.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1977

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fumitada Yamamoto: Innovator in Cerebral Vasodilators

Introduction

Fumitada Yamamoto is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of cerebral vasodilators. His innovative work has led to the creation of unique compounds that have potential therapeutic applications.

Latest Patents

Yamamoto holds a patent for Adamantane-piperazine derivatives. These derivatives are represented by a specific chemical formula, wherein R₁ is either a particular group or a --CH₂-- chain, and R₂ can be another defined group or a --CH₂CH=CH-- chain. The derivatives developed by Yamamoto serve as cerebral vasodilators or intermediates for the same, showcasing his expertise in this specialized area.

Career Highlights

Throughout his career, Fumitada Yamamoto has worked with prominent companies in the pharmaceutical industry. He has been associated with Idemitsu Kosan Company, Limited and Nippon Chemiphar Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in drug development.

Collaborations

Yamamoto has collaborated with esteemed colleagues, including Michio Sugimoto and Kosaku Honna. These partnerships have fostered a collaborative environment that has enhanced the research and development of innovative compounds.

Conclusion

Fumitada Yamamoto's contributions to the field of cerebral vasodilators through his patented innovations highlight his role as a key figure in medicinal chemistry. His work continues to influence the development of therapeutic agents that may benefit patients in the future.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…